Industry Briefs: November 26, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Briefs: November 26, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.


Company News

Algeta and Ablynx have formed a research collaboration to evaluate the potential of novel alpha-pharmaceuticals comprising thorium-227 conjugated to tumor-targeting Nanobodies, a proprietary group of antibody-derived proteins. Read More

Cleveland BioLabs and Panacela Labs have announced an award of a contract valued at 146 million rubles ($4.6 million), with the Ministry of Industry and Trade of the Russian Federation for the development of Xenomycins, a family of compounds in development as anti-infective agents. Read More

Impax Laboratories will collaborate with Perrigo Company on the development, manufacturing, and commercialization of an extended topical generic-drug product. Read More

Unigene Laboratories and Tarix Pharmaceuticals have entered into a definitive licensing agreement to develop an oral formulation of TXA127, Tarix’s lead peptide drug candidate Read More

People News

Cambridge Major Laboratories has appointed Prasad Raje as vice-president of science and technology. Read More

Dr. Reddy’s Laboratories has appointed Umang Vohra as executive vice-president and head of the company’s North America generic-drug business, effective January 2013, and Saumen Chakraborty as chief financial officer, effective Jan. 2, 2013. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
30%
Breakthrough designations
9%
Protecting the supply chain
39%
Expedited reviews of drug submissions
9%
More stakeholder involvement
13%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here